Class I histone deacetylases (HDACs) are key regulators of cell proliferation and they are frequently dysregulated in cancer cells. We report here the synthesis of a novel series of class-I selective HDAC inhibitors (HDACi) containing a 2-aminobenzamide moiety as a zinc-binding group connected with a central (piperazin-1-yl)pyrazine or (piperazin-1-yl)pyrimidine moiety. Some of the compounds were additionally substituted with an aromatic capping group. Compounds were tested in vitro against human HDAC1, 2, 3, and 8 enzymes and compared to reference class I HDACi (Entinostat (MS-275), Mocetinostat, CI994 and RGFP-966). The most promising compounds were found to be highly selective against HDAC1, 2 and 3 over the remaining HDAC subtypes from other classes. Molecular docking studies and MD simulations were performed to rationalize the in vitro data and to deduce a complete structure activity relationship (SAR) analysis of this novel series of class-I HDACi. The most potent compounds, including 19f, which blocks HDAC1, HDAC2, and HDAC3, as well as the selective HDAC1/HDAC2 inhibitors 21a and 29b, were selected for further cellular testing against human acute myeloid leukemia (AML) and erythroleukemic cancer (HEL) cells, taking into consideration their low toxicity against human embryonic HEK293 cells. We found that 19f is superior to the clinically tested class-I HDACi Entinostat (MS-275). Thus, 19f is a new and specific HDACi with the potential to eliminate blood cancer cells of various origins.
We developed a one-step direct assay for the determination of histone deacylase (HDAC) activity by substituting the carbonyl oxygen of the acyl moiety with sulfur, resulting in thioacylated lysine side chains. This modification is recognized by class I HDACs with different efficiencies ranging from not accepted for HDAC1 to kinetic constants similar to that of the parent oxo substrate for HDAC8. Class II HDACs can hydrolyze thioacylated substrates with approximately 5−10-fold reduced k cat values, which resembles the effect of thioamide substitution in metallo-protease substrates. Class IV HDAC11 accepts thiomyristoyl modification less efficiently with an ∼5-fold reduced specificity constant. On the basis of the unique spectroscopic properties of thioamide bonds (strong absorption in spectral range of 260−280 nm and efficient fluorescence quenching), HDAC-mediated cleavage of thioamides could be followed by ultraviolet−visible and fluorescence spectroscopy in a continuous manner. The HDAC activity assay is compatible with microtiter plate-based screening formats up to 1536-well plates with Z′ factors of >0.75 and signal-to-noise ratios of >50. Using thioacylated lysine residues in p53-derived peptides, we optimized substrates for HDAC8 with a catalytic efficiency of >250000 M −1 s −1 , which are more than 100-fold more effective than most of the known substrates. We determined inhibition constants of several inhibitors for human HDACs using thioacylated peptidic substrates and found good correlation with the values from the literature. On the other hand, we could introduce N-methylated, N-acylated lysine residues as inhibitors for HDACs with an IC 50 value of 1 μM for an N-methylated, N-myristoylated peptide derivative and human HDAC11.
Histone deacetylase
11 (HDAC11) preferentially removes fatty acid
residues from lysine side chains in a peptide or protein environment.
Here, we report the development and validation of a continuous fluorescence-based
activity assay using an internally quenched TNFα-derived peptide
derivative as a substrate. The threonine residue in the +1 position
was replaced by the quencher amino acid 3′-nitro-l-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated
11-aminoundecanoic acid. The resulting peptide substrate enables fluorescence-based
direct and continuous readout of HDAC11-mediated amide bond cleavage
fully compatible with high-throughput screening formats. The Z′-factor is higher than 0.85 for the 15 μM
substrate concentration, and the signal-to-noise ratio exceeds 150
for 384-well plates. In the absence of NAD+, this substrate
is specific for HDAC11. Reevaluation of inhibitory data using our
novel assay revealed limited potency and selectivity of known HDAC
inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor.
Histone
deacetylases (HDACs) are epigenetic regulators and additionally
control the activity of non-histone substrates. We recently demonstrated
that inhibition of HDAC8 overexpressed in various of cancers reduces
hepatocellular carcinoma tumorigenicity in a T cell-dependent manner.
Here, we present alkylated hydrazide-based class I HDAC inhibitors
in which the n-hexyl side chain attached to the hydrazide
moiety shows HDAC8 selectivity in vitro. Analysis
of the mode of inhibition of the most promising compound 7d against HDAC8 revealed a substrate-competitive binding mode. 7d marked induced acetylation of the HDAC8 substrates H3K27
and SMC3 but not tubulin in CD4+ T lymphocytes, and significantly
upregulated gene expressions for memory and effector functions. Furthermore,
intraperitoneal injection of 7d (10 mg/kg) in C57BL/6
mice increased interleukin-2 expression in CD4+ T cells and CD8+ T cell proportion with no apparent
toxicity. This study expands a novel chemotype of HDAC8 inhibitors
with T cell modulatory properties for future therapeutic applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.